Irhythm Technologies [IRTC] vs Boston Scientific [BSX] Detailed Stock Comparison
Irhythm Technologies
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Irhythm Technologies wins in 5 metrics, Boston Scientific wins in 13 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Irhythm Technologies | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -46.73 | 57.40 | Irhythm Technologies |
| Price-to-Book Ratio | 52.49 | 6.33 | Boston Scientific |
| Debt-to-Equity Ratio | 708.80 | 53.09 | Boston Scientific |
| PEG Ratio | 1.45 | 0.39 | Boston Scientific |
| EV/EBITDA | -118.79 | 33.24 | Irhythm Technologies |
| Profit Margin (TTM) | -14.06% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | -5.71% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | N/A | 18.63% | N/A |
| Return on Equity | -91.14% | 11.55% | Boston Scientific |
| Return on Assets (TTM) | -3.53% | 5.39% | Boston Scientific |
| Free Cash Flow (TTM) | $-45.55M | $2.37B | Boston Scientific |
| 1-Year Return | 177.16% | 13.82% | Irhythm Technologies |
| Price-to-Sales Ratio (TTM) | 8.35 | 7.72 | Boston Scientific |
| Enterprise Value | $5.63B | $156.39B | Boston Scientific |
| EV/Revenue Ratio | 8.57 | 8.46 | Boston Scientific |
| Gross Profit Margin (TTM) | 71.17% | 67.65% | Irhythm Technologies |
| Revenue per Share (TTM) | $21 | $13 | Irhythm Technologies |
| Earnings per Share (Diluted) | $-2.90 | $1.67 | Boston Scientific |
| Beta (Stock Volatility) | 1.11 | 0.66 | Boston Scientific |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Irhythm Technologies vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Irhythm Technologies | 3.80% | 1.42% | 1.60% | 21.73% | 60.44% | 94.33% |
| Boston Scientific | 0.39% | -1.96% | -9.79% | -7.15% | -3.83% | 7.65% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Irhythm Technologies | 177.16% | 41.39% | -30.99% | 573.94% | 573.94% | 573.94% |
| Boston Scientific | 13.82% | 142.00% | 133.88% | 470.02% | 1,469.66% | 307.71% |
News Based Sentiment: Irhythm Technologies vs Boston Scientific
Irhythm Technologies
News based Sentiment: MIXED
iRhythm experienced a strong second quarter with revenue growth and increased analyst price targets, but this was offset by significant insider selling and ongoing financial concerns, including a high debt load and negative profitability. The mixed signals create a complex investment picture requiring careful consideration.
Boston Scientific
News based Sentiment: POSITIVE
October brought a wave of positive signals for Boston Scientific, including increased institutional investment, raised price targets from multiple firms, and a promising long-range plan. While insider selling remains a point to watch, the overall narrative is one of strong growth potential and investor confidence.
Performance & Financial Health Analysis: Irhythm Technologies vs Boston Scientific
| Metric | IRTC | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $5.45B | $142.83B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 395,770 | 11,631,001 |
| 90 Day Avg. Volume | 396,597 | 9,170,397 |
| Last Close | $173.81 | $96.22 |
| 52 Week Range | $55.92 - $187.57 | $80.64 - $109.50 |
| % from 52W High | -7.34% | -12.13% |
| All-Time High | $286.19 (Jan 25, 2021) | $109.50 (Sep 09, 2025) |
| % from All-Time High | -39.27% | -12.13% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.26% | 0.23% |
| Quarterly Earnings Growth | 0.26% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | -0.14% | 0.14% |
| Operating Margin (TTM) | -0.06% | 0.19% |
| Return on Equity (TTM) | -0.91% | 0.12% |
| Debt to Equity (MRQ) | 708.80 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.23 | $15.14 |
| Cash per Share (MRQ) | $16.98 | $0.36 |
| Operating Cash Flow (TTM) | $63.35M | $4.28B |
| Levered Free Cash Flow (TTM) | $47.56M | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Irhythm Technologies vs Boston Scientific
| Metric | IRTC | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -46.73 | 57.40 |
| Forward P/E | -92.12 | 34.35 |
| PEG Ratio | 1.45 | 0.39 |
| Price to Sales (TTM) | 8.35 | 7.72 |
| Price to Book (MRQ) | 52.49 | 6.33 |
| Market Capitalization | ||
| Market Capitalization | $5.45B | $142.83B |
| Enterprise Value | $5.63B | $156.39B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.57 | 8.46 |
| Enterprise to EBITDA | -118.79 | 33.24 |
| Risk & Other Metrics | ||
| Beta | 1.11 | 0.66 |
| Book Value per Share (MRQ) | $3.23 | $15.14 |
Financial Statements Comparison: Irhythm Technologies vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IRTC | BSX |
|---|---|---|
| Revenue/Sales | $158.68M | $4.66B |
| Cost of Goods Sold | $49.46M | $1.45B |
| Gross Profit | $109.22M | $3.21B |
| Research & Development | $21.82M | $443.00M |
| Operating Income (EBIT) | $-32.56M | $937.00M |
| EBITDA | $-20.95M | $1.23B |
| Pre-Tax Income | $-30.04M | $805.00M |
| Income Tax | $665,000 | $133.00M |
| Net Income (Profit) | $-30.70M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IRTC | BSX |
|---|---|---|
| Cash & Equivalents | $375.28M | $725.00M |
| Total Current Assets | $636.01M | $7.34B |
| Total Current Liabilities | $111.34M | $5.06B |
| Long-Term Debt | $719.36M | $10.93B |
| Total Shareholders Equity | $86.67M | $22.45B |
| Retained Earnings | $-789.60M | $3.35B |
| Property, Plant & Equipment | $55.71M | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IRTC | BSX |
|---|---|---|
| Operating Cash Flow | $-31.20M | $513.00M |
| Capital Expenditures | $-9.42M | $-187.00M |
| Free Cash Flow | $-17.31M | $277.00M |
| Debt Repayment | $0 | $-1.31B |
| Common Stock Repurchase | $0 | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IRTC | BSX |
|---|---|---|
| Shares Short | 2.66M | 19.02M |
| Short Ratio | 6.69 | 2.76 |
| Short % of Float | 0.09% | 0.01% |
| Average Daily Volume (10 Day) | 395,770 | 11,631,001 |
| Average Daily Volume (90 Day) | 396,597 | 9,170,397 |
| Shares Outstanding | 31.39M | 1.47B |
| Float Shares | 31.75M | 1.48B |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.17% | 0.94% |
Dividend Analysis & Yield Comparison: Irhythm Technologies vs Boston Scientific
| Metric | IRTC | BSX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |